BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its CardiAMP autologous mononuclear cell therapy platform targets ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina from chronic myocardial ischemia. Its allogeneic mesenchymal stem cell (MSC) platform targets ischemic inflammatory HFrEF and ARDS. Products are enabled by the Helix transendocardial biotherapeutic delivery system for minimally invasive catheter-based intramyocardial delivery.
Q2 FY2026 — expected 2026-09-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-24 | 2025-12-31 | 0001437749-26-009587 | EDGAR | 83K words |
| 2025-03-26 | 2024-12-31 | 0001437749-25-009397 | EDGAR | — |
| 2024-03-27 | 2023-12-31 | 0001437749-24-009587 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0001437749-23-008312 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001437749-22-007544 | EDGAR | — |
| 2021-03-30 | 2020-12-31 | 0001437749-21-007543 | EDGAR | — |
| 2020-04-09 | 2019-12-31 | 0001437749-20-007405 | EDGAR | — |
| 2019-04-02 | 2018-12-31 | 0001437749-19-006300 | EDGAR | — |
| 2018-03-16 | 2017-12-31 | 0001437749-18-004870 | EDGAR | — |
| 2017-03-30 | 2016-12-31 | 0001437749-17-005643 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001437749-25-034437 | EDGAR | 16K words |
| 2025-08-11 | 2025-06-30 | 0001437749-25-025826 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001437749-25-016831 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001437749-24-034896 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001437749-24-026310 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001437749-24-016611 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001437749-23-030938 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001437749-23-022780 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001437749-23-013580 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001437749-22-026591 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001437749-22-019788 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001437749-22-011905 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001437749-26-010967 | EDGAR | 1K words |
| 2026-03-24 | 0001437749-26-009609 | EDGAR | — |
| 2026-03-17 | 0001437749-26-008499 | EDGAR | — |
| 2026-03-03 | 0001437749-26-006481 | EDGAR | — |
| 2026-02-10 | 0001437749-26-003582 | EDGAR | — |
| 2026-02-03 | 0001437749-26-002723 | EDGAR | — |
| 2025-12-16 | 0001437749-25-037910 | EDGAR | — |
| 2025-12-03 | 0001437749-25-036711 | EDGAR | — |
| 2025-11-24 | 0001437749-25-036076 | EDGAR | — |
| 2025-11-12 | 0001437749-25-034442 | EDGAR | — |
360 total filings indexed. 328 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000925741 |
| Ticker | BCDA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.biocardia.com |
| Listed | 1995-10-25 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report